Free Trial

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics logo
$29.46 -0.53 (-1.77%)
(As of 02:58 PM ET)

Dyne Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
9

Based on 10 Wall Street analysts who have issued ratings for Dyne Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 1 has given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for DYN.

Consensus Price Target

$51.40
74.47% Upside
According to the 10 analysts' twelve-month price targets for Dyne Therapeutics, the average price target is $51.40. The highest price target for DYN is $66.00, while the lowest price target for DYN is $35.00. The average price target represents a forecasted upside of 74.47% from the current price of $29.46.
Get the Latest News and Ratings for DYN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Dyne Therapeutics and its competitors.

Sign Up

DYN Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
8 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$51.40$51.40$50.60$27.20
Forecasted Upside74.47% Upside53.94% Upside8.75% Upside158.56% Upside
Consensus Rating
Buy
Buy
Buy
Buy

DYN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DYN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Dyne Therapeutics Stock vs. The Competition

TypeDyne TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside71.39% Upside26,931.47% Upside9.83% Upside
News Sentiment Rating
Neutral News

See Recent DYN News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/13/2024Chardan Capital
1 of 5 stars
 Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00+46.50%
11/13/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$55.00 ➝ $55.00+83.95%
10/24/2024JPMorgan Chase & Co.
3 of 5 stars
 DowngradeOverweight ➝ Neutral$43.00 ➝ $35.00+8.16%
9/23/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$53.00 ➝ $53.00+44.85%
9/3/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$55.00 ➝ $55.00+78.80%
8/16/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$41.00 ➝ $66.00+44.29%
8/15/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$45.00 ➝ $50.00+8.98%
8/14/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$48.00 ➝ $52.00+19.16%
5/20/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$36.00 ➝ $42.00+22.77%
1/4/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetStrong-Buy ➝ Strong-Buy$27.00 ➝ $56.00+279.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:16 PM ET.


DYN Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Dyne Therapeutics is $51.40, with a high forecast of $66.00 and a low forecast of $35.00.

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last twelve months. There is currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" DYN shares.

According to analysts, Dyne Therapeutics's stock has a predicted upside of 74.47% based on their 12-month stock forecasts.

Over the previous 90 days, Dyne Therapeutics's stock had 1 downgrade by analysts.

Dyne Therapeutics has been rated by research analysts at Chardan Capital, HC Wainwright, JPMorgan Chase & Co., Oppenheimer, and Piper Sandler in the past 90 days.

Analysts like Dyne Therapeutics more than other "medical" companies. The consensus rating for Dyne Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DYN compares to other companies.


This page (NASDAQ:DYN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners